Want to join the conversation?
$SMRT said gross profit for 2Q16 was $89.4MM or 28% of sale which compares to $88.9MM or 28.5% of sales from 2Q15. The lower rate reflects higher markdowns due to lower-than-planned sales & higher occupancy costs. $SMRT continued to manage 2Q16 SG&A expenses tightly, even with additional OpEx associated with having 5% more stores than last year.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.